Quarterly report pursuant to Section 13 or 15(d)

INTELLECTUAL PROPERTY/ LICENSING RIGHTS (Details Narrative)

v3.7.0.1
INTELLECTUAL PROPERTY/ LICENSING RIGHTS (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Oct. 01, 2015
Jul. 28, 2016
Jan. 26, 2016
Jun. 30, 2015
Mar. 31, 2017
Mar. 31, 2016
Dec. 31, 2016
Termination of licensing agreement         $ 132,804  
Intellectual property fees     $ 55,648        
Description for right to purchase perpetual rights     North America with the option for Central and South America for Naltrexone Implants formulas created by the Seller for 24 months upon receipt of the intellectual property for a fee of $55,648. The Company, within the first 12 months has the right to purchase perpetual rights for above territories for a one-time fee, financed over 5 years. The rights are amortized over the 24 month contract life.        
Amortization             $ 25,918
Common shares outstanding         239,711,285   181,804,501
Naltrexone Implant Formulation [Member]              
Estimated useful life       10 years      
Aggregate purchase price       $ 1,132,000      
Purchase obligation to pay       $ 1,000,000      
Acquired rights, title and interest payment period 14 months            
Common shares outstanding       3,000,000      
Market value       $ 0.044      
Therakine, Ltd. [Member]              
License cost   $ 2,750,000          
Aggregate purchase price   $ 250,000         $ 250,000
Escrow deposit             $ 75,000
Therakine, Ltd. [Member] | Minimum [Member]              
Sales of products   5.00%          
Therakine, Ltd. [Member] | Maximum [Member]              
Sales of products   12.00%